Neoantigens in cancer immunotherapy - PubMed (original) (raw)
Review
. 2015 Apr 3;348(6230):69-74.
doi: 10.1126/science.aaa4971.
Affiliations
- PMID: 25838375
- DOI: 10.1126/science.aaa4971
Review
Neoantigens in cancer immunotherapy
Ton N Schumacher et al. Science. 2015.
Abstract
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Copyright © 2015, American Association for the Advancement of Science.
Similar articles
- An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
Lam H, McNeil LK, Starobinets H, DeVault VL, Cohen RB, Twardowski P, Johnson ML, Gillison ML, Stein MN, Vaishampayan UN, DeCillis AP, Foti JJ, Vemulapalli V, Tjon E, Ferber K, DeOliveira DB, Broom W, Agnihotri P, Jaffee EM, Wong KK, Drake CG, Carroll PM, Davis TA, Flechtner JB. Lam H, et al. Cancer Discov. 2021 Mar;11(3):696-713. doi: 10.1158/2159-8290.CD-20-0377. Epub 2021 Jan 27. Cancer Discov. 2021. PMID: 33504579 - Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B. Chen F, et al. J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. Print 2019 May 1. J Clin Invest. 2019. PMID: 30835255 Free PMC article. - Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL. Nebot-Bral L, et al. Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Eur J Cancer. 2017. PMID: 28846956 Review. - Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. Peng M, et al. Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6. Mol Cancer. 2019. PMID: 31443694 Free PMC article. Review. - Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C, Xu S. Sun C, et al. Biosci Trends. 2020 Nov 4;14(5):349-353. doi: 10.5582/bst.2020.03267. Epub 2020 Sep 10. Biosci Trends. 2020. PMID: 32908077 Review.
Cited by
- Minireview: Novel Micropeptide Discovery by Proteomics and Deep Sequencing Methods.
Tharakan R, Sawa A. Tharakan R, et al. Front Genet. 2021 May 6;12:651485. doi: 10.3389/fgene.2021.651485. eCollection 2021. Front Genet. 2021. PMID: 34025718 Free PMC article. Review. - Industrializing engineered autologous T cells as medicines for solid tumours.
Britten CM, Shalabi A, Hoos A. Britten CM, et al. Nat Rev Drug Discov. 2021 Jun;20(6):476-488. doi: 10.1038/s41573-021-00175-8. Epub 2021 Apr 8. Nat Rev Drug Discov. 2021. PMID: 33833444 Review. - Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L, Chen F, Liu R, Shi L, Zhao G, Yan Z. Wang L, et al. BMC Cancer. 2021 Apr 9;21(1):379. doi: 10.1186/s12885-021-08083-1. BMC Cancer. 2021. PMID: 33836680 Free PMC article. - Challenges in bioinformatics approaches to tumor mutation burden analysis.
Fenizia F, Pasquale R, Abate RE, Lambiase M, Roma C, Bergantino F, Chaudhury R, Hyland F, Allen C, Normanno N. Fenizia F, et al. Oncol Lett. 2021 Jul;22(1):555. doi: 10.3892/ol.2021.12816. Epub 2021 May 24. Oncol Lett. 2021. PMID: 34084222 Free PMC article. - Bispecific antibodies targeting mutant RAS neoantigens.
Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Douglass J, et al. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. Sci Immunol. 2021. PMID: 33649101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources